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Inframe insertion and deletion mutations (indels) are commonly observed in 
cancer samples accounting for over 1% of all reported mutations. Few somatic 
inframe indels have been clinically documented as pathogenic and at present 
there are few tools to predict which indels drive cancer development. However, 
indels are a common feature of hereditary disease and several tools have been 
developed to predict the impact of inframe indels on protein function. In this 
study, we test whether six of the popular prediction tools can be adapted to test 
for cancer driver mutations and then develop a new algorithm (IndelRF) that 
discriminates between recurrent indels in known cancer genes and indels not 
associated with disease. IndelRF was developed to try and identify somatic, 
driver, and inframe indel mutations. Using a random forest classifier with 11 
features, IndelRF achieved accuracies of 0.995 and 0.968 for insertion and 
deletion mutations, respectively. Finally, we use IndelRF to classify the inframe 
indel cancer mutations in the MOKCa database. 
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Most cancers are formed as a result of genetic mutations in DNA sequences in critical 
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genes that confer a selective advantage to tumour cells (Futreal et al. (2004)). These 
coding mutations can be caused by error in DNA replication and repair, and 
environmental factors that alter the genetic structure of somatic cells. Understanding 
the impact of these mutations is vital for providing a platform to understand cancer 
initiation, progression and therapeutic strategies (Hindorff et al. (2009), Ferrer-Costa 
et al. (2004)). 
Commonly observed somatic variations in cancer include single nucleotide variants 
(SNV) and small insertions and deletions (Indels). Indels are the second most 
common type of mutations after SNVs with over two times as many deletions as 
insertions occurring in most cancers (Stenson et al. (2009)). Indels can affect protein 
function and contribute to cancer development (Akagi et al. (2010)). 
Two types of indels are found in protein coding regions; frameshift and inframe 
mutations. Indels that cause frameshifts have a length not divisible by 3, they change 
the reading frame of the DNA and generally result in a change to the amino acid 
sequence, followed by a premature stop codon and a truncated transcript.  Indels that 
have a length divisible by 3 are called in-frame indels and cause insertions and 
deletions of small runs of amino acids (Mullaney et al. (2010)). 
Cancer mutations, including indels are considered driver mutations if they give the 
cells a selective growth advantage and contribute to the initiation or progression of the 
disease. Passenger mutations do not contribute to the disease progression per se, but 
occur due to the inherent genetic instability of the tumour (Greenman et al. (2007)). 
Driver mutations that contribute in tumorigenesis are normally found in genes 
described as oncogenes or tumour suppressor genes depending on their role in cancer 
development (Futreal et al. (2004)). 
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Although the majority of computational tools developed for assessing genetic 
mutations have focused on missense mutations, more recently, there have been 
several efforts to predict the impact of in-frame indel mutations on protein function or 
structure using a variety of strategies. Commonly used algorithms that predict the 
pathogenicity of impact of indels include; PROVEAN (Choi and Chan (2015)) SIFT 
(Hu and Ng (2013)), VEST-Indel (Douville et al. (2016)), CADD (Kircher et al. 
(2014)), DDIG-In (Zhao et al. (2013)), PaPI (Limongelli et al. (2015)) and PinPor 
(Zhang et al. (2014)).   
Most of these methods classify each mutation according to two state categories; 
neutral or pathogenic using a variety of machine learning techniques including a J48 
Decision Tree (SIFT-indel), Random Forest and Logistic Regression (PaPi) and 
Bayesian networks (PinPor), with reported AUC ROC accuracies varying from 0.75 
to 0.9 on a variety of datasets (see Table 1). 
The pathogenic mutations are generally derived from The Human Gene Mutation 
Database (HGMD) (Stenson et al. (2009)) a catalogue of gene lesions responsible for 
human inherited disease (e.g. SIFT-indel, VEST-indel, DDID-In, PaPI, PinPor) or 
from UniProt (PROVEAN). Neutral mutations are generally derived from the 1,000 
Genomes Project (Genomes Project et al. (2010)), the Exome Sequencing Project 
(ESP) (Tennessen et al. (2012)) or by identifying tolerated mutations from the 
sequence alignment of human sequences with other mammalian species (e.g. SIFT-
indel).  CADD uses a slightly alternative approach that discriminates fixed or nearly 
fixed derived alleles in human from a set of simulated mutations. This method was 
developed to predict deleterious mutations rather than the functional effect on protein 
or variant pathogenicity using a support vector machine classifier (Kircher et al. 
(2014)). 
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In this study, rather than studying genetic mutations from model organisms and 
inherited disease genes, we wanted to develop a method for determining driver indel 
mutations specifically for somatic mutations in cancer. However, few insertion and 
deletion mutations have been clinically documented as pathogenic in cancer.  For 
instance in the ClinVar database (Landrum et al. (2014)), only 20 inframe insertions 
and 108 inframe deletions are described as pathogenic and there even fewer reported 
somatic driver mutations (8 and 26, respectively). 
Recurrence is often used to imply clinical driver status to cancer mutations (Landrum 
et al. (2014)). So to identify set of somatic indel mutations that were likely to 
contribute to the development of cancer we decided to use recurrence. We identified a 
set of recurrent somatic indels found in exome sequencing of documented cancer 
genes.  We investigated the ability of current prediction algorithms to distinguish 
between these recurrent mutations and neutral indel mutations found to have little or 
no effect on protein function. We then defined an ‘optimal’ training set of cancer 
mutations that could be used in algorithms that predict whether an indel is 
contributing to the development of cancer.  
An automated classifier was developed to distinguish between deleterious and neutral 
mutations using 11 features to describe each mutation. We selected a random forest 
classifier that achieved the best result to classify pathogenic and neutral mutations for 
insertions and deletions respectively. We validated our approach by testing our 
algorithm using indels clinically identified as disease causing deposited in the ClinVar 
database.  Finally, we ran our algorithm (IndelRF) classifier to classify the predicted 






To identify recurrent mutations, in-frame insertions and deletions (indels) were 
extracted from the COSMIC database v82 using annotations form the Ensembl human 
genome build hg38 (Bamford et al. (2004)). Mutations were also extracted for the 
hg37 build of the Ensembl database for use with the PaPI, DDIG-in and PinPor 
algorithms. 
Clinically determined cancer mutations were downloaded from the ClinVar database 
(Landrum et al. (2014)) with indels that were labelled as pathogenic or probably 
pathogenic considered pathogenic.   
For the neutral set of mutation we identified a set of indels that derived from the 1000 
Genomes Project and the Exome Sequencing Project (ESP) that are commonly 
observed in the human population (Hu and Ng (2013)). To make sure that our trained 
datasets were balanced, no more than 10% of the mutations within a class were taken 
from a single protein or a domain type. 
 
Identification of hotspot indel mutations 
To identify indels that were likely to be pathogenic, we identified hotspot mutations. 
For each protein in the human exome, we computed the total number of mutations it 
contained and the frequency of mutation at each position.  A binomial test was used to 
identify which positions had a significant number of mutations (See supplementary 
methods). Insertion and deletion were tested independently and only positions where 




Comparison of prediction algorithms 
We assessed six different algorithms that have been developed to predict the impact 
of in-frame indel mutations on the protein function and structure. These algorithms 
were: CADD (Kircher et al. (2014)), DDIG-In (Zhao et al. (2013)), PaPI (Limongelli 
et al. (2015)), PinPor (Zhang et al. (2014)), SIFT-indel (Hu and Ng (2013)) and VEST 
(Douville et al. (2016)). 
Feature selection  
We derived features from four existing prediction algorithms: VEST, PinPor, CADD 
and Pseudo Amino Acid Variant Predictor (PaPI). In total, we calculated 11 features 
for each mutation (See supplementary Table S1).  These features describe the 
evolutionary conservation of the sequence where the insertion or deletion occurs, in a 
variety of ways, or the pathogenicity of the mutation. 
Feature Importance  
Mean decrease accuracy was measured to identify the variable importance using the 
random forest package (Archer and Kimes (2008)). The values of each of the 
variables in turn are randomly permuted for the out-of-bag observations, and then the 
modified data are passed down the tree to get new predictions. The importance of the 
variable is the difference in misclassification rate for the modified and original data, 
divided by the standard error (See supplementary methods). 
 
Machine learning 
All datasets were balanced to remove protein and domain biases in the data set.  No 
more than 15% of mutations were allowed from a single protein or a domain family. 
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A random forest classifier was trained to classify pathogenic and neutral indel 
mutations using R version 3.2.3. Binary classifications were calculated for in-frame 
insertion and in-frame deletion, independently. It was run with ten fold cross 
validation and the parameters optimised for each model.  
We also trained a support vector machine classifier (SVM) using 10-fold cross 
validation to optimise the hyperparameter C, used to trade off between variable 
minimization and margin maximization, and choose the kernel type that best fit our 
data.   
The classifier with the best accuracy at discriminating between pathogenic and neutral 
mutations for both insertion and deletions was a random forest machine classifier that 
we have named IndelRF. 
 
Validation of algorithms 
We validated the performance of IndelRF and compared it to exisiting algorithms 
using test sets from ClinVar database (Landrum et al. (2016)).   Predictions were 
generated using standard settings and the public web servers. Sensitivity (TP/TP+FN), 
specificity (TN/TN+FP) and accuracy (TP+TN/TP+TN+FP+FN) were measured to 
compare the performance of methods. We also calculated area under the curve (AUC) 
of receiver Operating Characteristic (ROC) curve for insertions and deletions 
separately. 
 
Prediction of functional consequences of indel mutations in the MOKCa 
database 
5437 in-frame indel mutations were downloaded from MOKCa database v21 
(Richardson et al. (2009)). 1167 of them were insertions and 4270 deletion mutations. 
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IndelRF was used to predict whether the mutations were pathogenic and likely to be 
cancer drivers. We also identified the pathogenic mutations found in oncogenes and 
tumour suppressors as described by the Cancer Gene Census (Futreal et al. (2004)). 
 
Results and Discussion 
Identification of recurrent indels 
4435 in-frame insertion mutations and 14456 in-frame deletion mutations were 
reported in the COSMIC database.  This led to 909 recurrently mutated positions 
having inframe insertions and 2587 inframe deletions. As more than one indel could 
be reported at each amino acid position in total, there were 1856 inframe insertions 
and 2766 inframe mutations that we used to compare the performances of the six 
published algorithms.   
Comparison of Prediction Algorithms  
Ease of use 
The number of results successfully calculated by the prediction algorithms for each of 
the insertion and deletion mutations, are shown in supplementary Tables S2 and S3 
and Supplementary figure 1.  Clearly, the algorithms did not work on all COSMIC 
annotations of the mutations. Often the reason was incomplete nomenclature.  For 
instance, missing bases in the input sequences for deletions caused some algorithms to 
falter. The entries CTNNB1, c.14_241del228, FOXP1 c.1553_1564del12 did not give 
results, as the sequence of the deleted DNA was absent from the entry. 
There may have also been discrepancies in genomic location of the mutation that was 
required for the programs due to differences in versions of the genome build used to 
define the mutation and that the prediction algorithm used. 
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Are recurrent mutations pathogenic?  
In total pathogenicity values could be calculated for 898 inframe insertions and 962 
inframe deletions predictions for all 6 programs available (See supplementary Figure 
S1).  The algorithms predicted between 27%-62% insertion mutations and between 
33%-73% deletion mutations as pathogenic. In total 74 inframe insertions and 109 
inframe deletions mutations were predicted as pathogenic by all 6 algorithms (Figure 
1). DDIG-in predicted the least number of the indels to be pathogenic whereas PaPI 
identified the most number of indels to be pathogenic.     
Definition of optimal somatic cancer pathogenic indel datasets 
To compare the variation between the algorithms, we selected 98 recurrent insertion 
mutations and 155 recurrent deletion mutations that had been predicted to be 
pathogenic by at least four of the 6 programs, as our putative pathogenic driver indel 
datasets.  This reduction in the number of mutations was to remove protein and 
domain biases in the data set so that no more than 15% of mutations within a dataset 
were allowed from a single protein or a domain family. 
When using the algorithms to distinguish between our somatic driver pathogenic 
indels and a neutral set of mutations, most of the algorithms performed well with 
accuracy scores ranging from 0.753 to 0.988, and similarly to their published 
performances on indels linked to hereditary disease. (see Table 1). The DDIG-in 
algorithm performed the best on these examples, discriminating well between the 
recurrent somatic cancer mutations and the neutral mutations for both in-frame indels. 
(Hu and Ng (2013)).  The only exception was PinPor that had accuracy scores of 
0.534 for insertions and 0.553 for deletions.  PinPor differs to the other prediction 
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algorithms as it predicts the pathogenicity of indels by assessing the impact of 
mutations on post-transcriptional regulation rather than impact on the protein 
structure.   
 
Development of a cancer specific indel classifier 
Evaluation of our datasets by existing algorithms suggest that the recurrent somatic 
cancer mutations are pathogenic and therefore may be drivers in cancer.  We then 
used these cancer specific datasets to train machine algorithms to enable us to detect 
other driver indel mutations. 
Two different models, random forest and support vector machine classifiers, were 
trialed and compared. Binary classifications were calculated for pathogenic/neutral 
classes in in-frame insertion and deletion, independently. 
We used a random forest classifier using 10-fold cross-validation to optimise 
classifier hyperparameters and assess performance for each class.    
The random forest classifier has two parameters, depth and number of trees that affect 
on the accuracy of a classifier (Bosch et al. (2007)).  The results show how the 
changing of both the number of trees and the depth of these trees affect the accuracy 
(See supplementary Tables S6 & S7) however the classification accuracy is generally 
high. The highest accuracy is 0.995 when the depth is 100 and the number of trees is 
100 in insertion and 0.968 with a depth of 10 and 1000 tree for deletion mutations. 
We also trialled a support vector machine classifier however all our random forest 
classifier performed better than our SVM classifier for insertion and deletion 
mutations. We found the highest accuracy of 0.983 and 0.962 with a radial basis 
function (RBF) kernel for insertion and deletion, respectively.  The RBF kernel is the 
simplest kernel that can be used and generalizes good results (Suykens and 
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Vandewalle (1999, Keerthi and Lin (2003)) SVM classifier yielded the best result 
using RBF kernel. 
The results for the SVM hyperparameter optimisation show that different values of 
hyperparameters in insertion and deletion mutations do not significantly change 
accuracy scores except when the polynomial kernel is used which caused the 
classifier to have a lower accuracy of 0.658 and 0.654, respectively (See 
supplementary Tables S8 & S9).   
However, the classifier with the highest accuracy at discriminating pathogenic and 
neutral classes in insertions and deletions was a random forest classifier.  
Feature importance 
Having successfully designed an algorithm that could reliably distinguish between 
recurrent somatic cancer mutations and neutral insertion/deletion mutations we 
decided to identify the important features. Mean decrease accuracy is one of the 
popular feature selection methods that directly measure the effect of each feature on 
the accuracy of random forest. It permutes the values of one feature while others are 
left unchanged and measure how much the permutation reduces the accuracy (Cutler 
et al. (2007)).  
Figure 2 shows that VEST p-value, priPhCons, Phylop and Gerp++ were the four best 
performing features for insertion and deletion. VEST p-value score, from VEST 
prediction algorithm, is the probability that benign mutation is misclassified as 
pathogenic. Primate PhastCons conservation score (priPhCons) was one of the top 
five features from CADD. Phylop and Gerp++ scores, from PaPI algorithm, are two 
of the evolutionary conservation score that apply different and complementary 
methods to weight nucleotide conservation among different species (Garber et al. 
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(2009)).  
Moreover, the distance of indel mutation to the exon’s 3’ end was one of the most 
important features for insertions. Similarity, when comparing pathogenic versus 
neutral mutation for deletions, one of the top five features was the distance of indel to 
exon’s 5’ end. 
 
Evaluation test set  
We applied our algorithms to the pathogenic insertions/deletions identified in the 
ClinVar databases as an independent evaluation set. For somatic insertion indels, 18 
pathogenic mutations and seven somatic-pathogenic mutations were evaluated using 
(IndelRF) with accuracies of 0.833 and 1.000, respectively. IndelRF was alos 
evaluated on cancer germline mutations; 72 deletion insertion 19 deletions and gave 
accuracies of 0.972 and 1.000, respectively. IndelRF outperformed the existing 
algorithms in these datasets (see Table 2). 
Identifying pathogenic in-frame indel mutations in MOKCa 
We applied IndelRF to the in-frame indels identified in the MOKCa database. 844 
unique insertions and 1790 deletion mutations were identified. Of these (46%) 392 
insertions were predicted to be pathogenic in 251 genes, and 848 (47%) deletions 
across 611 genes. 
Analysis of pathogenic mutations 
Based on the cancer gene classification in the Cancer Gene Census (Futreal et al. 
(2004)) we identified a set of 98 deletions in 37 oncogenes (OG) and 134 deletions 
across 31 tumour suppressors (TS) that were predicted to be  pathogenic deletions 
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(see supplementary Tables S10 & S11).  This suggests that indels can be both 
activating in oncogenes, as well as causing gene disruption in tumour suppressors. 
We also detected 80 putative activating insertions across 26 oncogenes and 69 
inactivating insertions across 18 tumour suppressors (See supplementary Tables S12 
& S13).   
Below are some of the indels predicted to be pathogenic, confirmed by reports in the 
literature 
EGFR p.L747_E749delLRE  
Epidermal growth factor receptor (EGFR) is an oncogene that regulates cell 
proliferation. Mutations in EGFR activate the EGFR signaling pathway and promote 
EGFR-mediated pro-survival and anti-apoptotic signals through down-stream targets 
such as RAS, RAF and MEK (Zhang et al. (2010)). The most abundant EGFR 
mutations are deletions in the kinase domain in exon 19 (residues 747 - 752) and 
constitute about 45% of all EGFR mutations (Zhang et al. (2010)).   These mutations 
are thought to produce a conformational predisposition for the kinase to prefer its 
activate conformation, and hence become constitutively  active.  
 
JAK2 p.E543_D544del 
Similarly Janus kinase 2 (Jak2) is oncogene that promotes the growth and division of 
cells. Jak2 mutations define a distinct myeloproliferative syndrome that affects 
patients with a diagnosis of polycythemia vera (PV) (Scott et al. (2007)). A small 
faction of polycythemia vera (PV) patients (<5%) carry usually deletions mutations in 
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JAK2 at exon 12 (Cazzola and Kralovics (2014, Tefferi and Pardanani (2015)) at 
residues E543 (Scott et al. (2007)).  
KRAS p.G10_A11insG 
KRAS is one of the RAS superfamily that act as oncogenes. It helps regulate cell 
growth.  When mutated cell signaling is disrupted leading to uncontrolled cell 
proliferation and the development of cancer. KRAS insertion mutations have been 
observed between codons 10 and 11 (KRAS p.G10_A11insG) in one pateint with 
colorectal cancer (Tong et al. (2014)) and also in one myeloid leukaemia patient 
(Bollag et al. (1996)).   
ARIA1A p.Q1334delQ 
AT-rich interactive domain 1A (ARID1A) is a tumour suppressor that has been 
recognised in several types of human cancers. About 5% of ARID1A somatic 
mutations are in-frame indels (Guan et al. (2012)). Deletion mutations at position 
Q1334del were found two tumours; gastric carcinoma (Jones et al. (2012)) and 
prostate carcinoma (Wang et al. (2011)).   
Conclusions 
In this study, we sought to develop machine-learning models to identify pathogenic 
in-frame indels. We compared the ability of six prediction tools to discriminate 
between these pathogenic mutations and a set of neutral mutations, which they all did 
with ease.  
We then developed our own classifiers that could discriminate pathogenic mutations 
with an accuracy of 0.995 and 0.968 for insertions and deletions, respectively.  The 
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most four important features of our classifiers were the VEST p-value, priPhCons, 
Phylop and Gerp++ of in-frame insertion and deletion mutations.   
Finally, we have used our algorithms to predict the functional consequence of 844 
insertion mutations and 1790 deletion mutations documented in the MOKCa database. 
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Previously published Insertion Deletion 
*Sen. *Spe. *Acc. *AUC *Sen. *Spe. *Acc. *AUC *Sen. *Spe. *Acc. *AUC 
CADD NA NA NA 0.88 0.853 0.653 0.753 0.845 0.883 0.715 0.799 0.895 
DDIG-in 0.89 NA 0.83 0.89 1.00 0.976 0.988 0.991 1.00 0.936 0.967 0.975 
PaPI 0.86 0.86 0.86 0.92 0.915 0.653 0.784 0.841 0.883 0.837 0.860 0.914 
PinPor NA NA 0.75 0.83 0.830 0.238 0.534 0.533 0.680 0.389 0.534 0.553 
SIFT-Indel 0.81 0.82 0.82 0.87 0.892 0.768 0.830 0.730 0.964 0.578 0.771 0.654 
VEST-indel 0.90 0.90 0.90 0.91 0.923 0.700 0.811 0.886 0.982 0.872 0.927 0.973 
 
Table 1.  Comparing the performance of in-frame insertion and deletion with previously published results. 








 Insertion Deletion 
Pathogenic Somatic Pathogenic Somatic 
CADD 0.28 1.00 0.88 0.84 
DDIG-in 0.56 1.00 0.86 0.84 
PaPI 0.77 0.75 0.97 1.00 
PinPor 0.72 1.00 0.71 0.79 
SIFT-indel 0.83 1.00 0.82 0.84 
VEST-indel 0.77 1.00 0.95 0.94 
IndelRF 0.83 1.00 0.97 1.00 
 


































Figure 1. Common pathogenic mutations between six algorithms in inframe indels.  





Figure 2. The importance features across insertions and deletions.  
The features are ranked according to insertion mutations with the corresponding key 
at the side. 
 
